20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Apnimed, Inc. Common Stock (APMD) operates in the BIOTECHNOLOGY industry and is headquartered in Cambridge, United States with about 81 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, APMD reported $38M in revenue and ($1M) in net income.
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets.
Interactive charts & full statements → Open the APMD valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 |
|---|---|---|---|
| Total Revenue | $117M | $38M | $8M |
| Gross Profit | $111M | $32M | $5M |
| Gross Margin % | 94.5% | 82.6% | 58.0% |
| Operating Income (EBIT) | $23M | ($54M) | ($114M) |
| Operating Margin % | 19.9% | -139.9% | -1425.8% |
| Net Income | $98M | ($1M) | ($111M) |
| Net Margin % | 83.8% | -2.4% | -1389.2% |
| EBITDA | — | — | — |
| Earnings Per Share (EPS) | — | $-0.02 | $-2.79 |
| Shares Outstanding (M) | 40M | 40M | 40M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Total Revenue | $12M | $85M | $17M | $3M |
| Gross Profit | $11M | $83M | $15M | $2M |
| Gross Margin % | 90.0% | 97.5% | 89.9% | 57.9% |
| Operating Income (EBIT) | ($12M) | $68M | ($6M) | ($27M) |
| Operating Margin % | -96.9% | 80.2% | -34.7% | -865.9% |
| Net Income | $126M | $70M | ($69M) | ($29M) |
| Net Margin % | 1042.5% | 83.0% | -406.0% | -914.9% |
| EBITDA | — | — | — | — |
| Earnings Per Share (EPS) | $3.16 | $1.77 | — | — |
| Shares Outstanding (M) | 40M | 40M | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 |
|---|---|---|---|
| Cash from Operations (CFO) | ($84M) | ($78M) | ($110M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($84M) | ($78M) | ($110M) |
| FCF Margin % | -71.5% | -202.3% | -1376.4% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Cash from Operations (CFO) | ($18M) | ($20M) | ($17M) | ($28M) |
| Free Cash Flow (FCF) | ($18M) | ($20M) | ($17M) | ($28M) |
| FCF Margin % | -149.9% | -23.4% | -101.5% | -908.7% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 |
|---|---|---|---|
| Total Assets | $195M | $73M | $109M |
| Cash & Cash Equivalents | $173M | $42M | $68M |
| Total Liabilities | $372M | $446M | $358M |
| Total Debt (Short + Long-Term) | $80M | $41M | $0M |
| Total Shareholders' Equity | ($176M) | ($373M) | ($249M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive APMD viewer.
About TickerBase · Data methodology & sources · Privacy · Terms